Microbot Medical’s Self-Cleaning Shunt (SCS™) Clearly Demonstrated the Ability to Prevent Shunt Occlusion in a Follow-up ...
10 Setembro 2019 - 8:30AM
Having successfully concluded an independent in-vitro laboratory
study and published the positive results earlier this year, the
operational effectiveness of Microbot Medical Inc.’s (NASDAQ: MBOT)
Self-Cleaning Shunt (SCS™) was validated in a broader follow-up
in-vitro lab study and clearly demonstrated the device’s capability
to prevent shunt occlusion under the parameters of that study.
“The data from this latest study brings us one
step closer to commercialization as it continues to demonstrate
that Microbot’s SCS™ offers a clear competitive differentiation
compared with current shunts being used today in thousands of
procedures,” commented Harel Gadot, CDEO, President and
Chairman. “Our SCS™ has the potential to yield better patient
outcomes, improve quality of life, positively influence multiple
stakeholders and lower healthcare costs.”
The follow-up study, which commenced in July
2019 and concluded on August 14, 2019, was conducted by Envigo CRS
Israel, a leading provider of non-clinical contract research
services and research models. Human brain glioblastoma cells
were used in order to assess performance of the SCS™ in a test
system with accelerated cell growth rate, accumulation and
obstruction rates. The study demonstrated:
- Significant cell growth and
accumulation in a non-operating SCS™ as well as a standard of
care surgical shunt.
- A significant inhibition in cell
growth in daily (5-10 minutes) or weekly (up to 2 hours over the
week) operating SCS™ with little cell attachment on the
robotic brush (ViRob™) and on the opening where the robotic brush
(ViRob™) operates.
- The effectiveness of the Company’s
SCS™ devices in preventing cells blockage as compare to standard of
care surgical shunts
Additionally, the Company remains on target to
complete and release the results of the pre-clinical studies to
further evaluate the safety and efficacy of the SCS™ being
performed at Wayne State University and Washington University
School of Medicine in St. Louis, during the fourth quarter of 2019
and the first quarter of 2020, respectively.
As a reminder, Mr. Gadot is presenting at the
Rodman & Renshaw Global Investment Conference today at 12:05 pm
(ET), at the Lotte New York Palace in New York City, where he will
share the summary results of the follow-up in-vitro laboratory
study as well demonstrating a working headset prototype of the
SCS™ device. A live webcast and subsequent archived replay of
the Company’s presentation may be accessed via the ‘Investors’
section, under ‘Presentations and Resources’ of the Company’s
website at www.microbotmedical.com.
About Envigo
Envigo CRS Israel provides comprehensive
scientific expertise and a full service offering in non-clinical
research and development, research models and services,
regulatory consulting, and analytical support to our customers.
Envigo is a privately held global company with corporate
headquarters in New Jersey.
About Microbot Medical,
Inc.
Microbot™, which was founded in 2010 and
commenced operations in 2011, became a NASDAQ listed company on
November 28, 2016. The Company specializes in transformational
micro-robotic medical technologies leveraging the natural and
artificial lumens within the human body. Microbot’s current
technological platforms, ViRob™, TipCAT™ and CardioSert™, are
comprised of three highly advanced technologies, from which the
Company is currently developing its first product candidate: The
Self-Cleaning Shunt, or ™, for the treatment of hydrocephalus and
Normal Pressure Hydrocephalus, or NPH. The Company also is focused
on the development of a Multi Generation Pipeline Portfolio (MGPP)
utilizing all technologies. Further information about Microbot
Medical is available at http://www.microbotmedical.com.
The ViRob™ technology is a revolutionary
autonomous crawling micro-robot which can be controlled remotely or
within the body. Its miniature dimensions allow it to navigate and
crawl in different spaces within the human body, including blood
vessels, the digestive tract and the respiratory system. Its unique
structure gives it the ability to move in tight spaces and curved
passages as well as the ability to remain within the human body for
prolonged time. To learn more about ViRob™ please visit
http://www.microbotmedical.com/technology/virob/.
TipCAT™ is a transformational
self-propelled, flexible, and semi-disposable locomotive device
providing see & treat capabilities within tubular lumens in the
human body such as the colon, blood vessels, and the urinary
tract. Its locomotion mechanism is perfectly suitable to
navigate and crawl through natural & artificial tubular lumens,
applying the minimal necessary pressure to achieve the adequate
friction required for gentle, fast, and safe advancement within the
human body. To learn more about TipCAT™, visit
http://www.microbotmedical.com/technology/tipcat/.
CardioSert™ technology contemplates a
unique combination of a guidewire and microcatheter, technologies
that are broadly used for endoluminal surgery. The
CardioSert™ technology features unique steering and stiffness
control capabilities, and it was originally developed to support
interventional cardiologists in crossing the most complex lesions
called chronic total occlusion (CTO) during percutaneous coronary
intervention (PCI) procedures and has the potential to be used in
other spaces and applications, such as peripheral intervention,
neurosurgery and urology. CardioSert™ was part of a
technological incubator supported by the Israel Innovation
Authorities (formerly known as the Office of the Chief Scientist,
or OCS), and its device has successfully completed pre-clinical
testing.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws.. Any statements that are not
historical fact (including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects” and “estimates”) should also be considered to be
forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, the outcome of its studies to evaluate the SCS and other
existing and future technologies, uncertainty in the results of
pre-clinical and clinical trials or regulatory pathways and
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the businesses of Microbot
Medical Inc. particularly those mentioned in the cautionary
statements found in Microbot Medical Inc.’s filings with the
Securities and Exchange Commission. Microbot Medical disclaims any
intent or obligation to update these forward-looking
statements.
Investor Contact:
Michael PolyviouEVC
Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024